Scarica l'app Stockscreener
44.50
1.57%
0.69
Dopo l'orario di chiusura:
44.64
0.14
+0.31%
Precedente Chiudi:
$43.81
Aprire:
$44.245
Volume 24 ore:
6.15M
Relative Volume:
1.69
Capitalizzazione di mercato:
$7.40B
Reddito:
$1.06B
Utile/perdita netta:
$-326.58M
Rapporto P/E:
-21.17
EPS:
-2.1022
Flusso di cassa netto:
$-977.73M
1 W Prestazione:
+0.14%
1M Prestazione:
-30.00%
6M Prestazione:
-38.79%
1 anno Prestazione:
-29.33%
Intervallo 1D:
$43.62
$45.28
Intervallo di 1 settimana:
$43.01
$46.41
Portata 52W:
$43.01
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
44.50 | 7.40B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide - finance.yahoo.com
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis - finance.yahoo.com
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data - Investing.com
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS) - The Globe and Mail
Oppenheimer reiterates Ionis stock rating on late-stage wins By Investing.com - Investing.com Canada
Ionis Pharmaceuticals, Inc. (IONS) Options ChainYahoo Finance - Yahoo! Finance Canada
Otsuka, Ionis notch phase III win in FUS-ALS - BioWorld News
IONIS Pharmaceuticals (NASDAQ: IONS) Announces Positive Interim Phase 3 Data for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Pharmaceuticals and Roche Announce Positive Phase 3 Interim Results for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
Roche, Ionis RNA drug scores in kidney disease study - BioPharma Dive
IONS Looks 5.2% Undervalued on GF Value™ Amid RNA Therapy Trial News - gurufocus.com
Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint - Mugglehead Investment Magazine
Otsuka, Ionis to Discuss Approval Path for FUS-ALS Drug With Regulators - GenomeWeb
Ionis Pharmaceuticals stock hits 52-week low at $44.20 By Investing.com - Investing.com India
Ionis Pharmaceuticals stock hits 52-week low at $44.20 - Investing.com
BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data By Investing.com - Investing.com Canada
Roche, Ionis post trial win for kidney drug (IONS:NASDAQ) - Seeking Alpha
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease - Benzinga
Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.com - Investing.com Nigeria
Canaccord reiterates Ionis stock rating on positive trial results By Investing.com - Investing.com Canada
Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy - TradingView
Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen - Yahoo
Otsuka and Ionis report positive Phase III readout for ulefnersen - The Pharma Letter
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - BioSpace
Ionis, Roche report positive phase 3 data for kidney drug - Investing.com
Ionis, Roche report positive phase 3 data for kidney drug By Investing.com - Investing.com Australia
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada
IONS Looks 7.0% Undervalued on GF Value™ - gurufocus.com
Ionis to Seek Expedited FDA Review for ALS Drug - Benzinga
IONS Looks 7.2% Undervalued on GF Value™ Amid Mixed Growth and P - gurufocus.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView
Otsuka, Ionis’ experimental ALS drug meets main goal in late-stage study - 101 WIXX
JPMorgan cuts Ionis Pharmaceuticals stock price target on launch concerns By Investing.com - Investing.com UK
Ionis drug meets primary goal in rare ALS gene mutation trial - Investing.com Canada
Ionis drug meets primary goal in rare ALS gene mutation trial By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile - TradingView
Ionis Pharmaceuticals Price Target Cut to $70.00/Share From $76.00 by JP Morgan - Moomoo
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - finance.yahoo.com
(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
High Growth Tech Stocks To Watch In The US September 2026 - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook On An 88.61% Potential Upside - DirectorsTalk Interviews
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - finance.yahoo.com
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Ionis Pharmaceuticals Stock Plummets Yet Analysts Remain Optimistic - Intellectia AI
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks - finance.yahoo.com
Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention? - Yahoo Finance
IONS Looks 6.5% Undervalued on GF Value™ Despite Challenging Fun - GuruFocus
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):